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ABSTRACT The retroviral proteases (PRs) have a struc-
tural feature called the f lap, which consists of a short anti-
parallel b-sheet with a turn. The flap extends over the
substrate binding cleft and must be f lexible to allow entry and
exit of the polypeptide substrates and products. We analyzed
the sequence requirements of the amino acids within the f lap
region (positions 46–56) of the HIV-1 PR. The phenotypes of
131 substitution mutants were determined using a bacterial
expression system. Four of the mutant PRs with mutations in
different regions of the f lap were selected for kinetic analysis.
Our phenotypic analysis, considered in the context of pub-
lished structures of the HIV-1 PR with a bound substrate
analogs, shows that: (i) Met-46 and Phe-53 participate in
hydrophobic interactions on the solvent-exposed face of the
f lap; (ii) Ile-47, Ile-54, and Val-56 participate in hydrophobic
interactions on the inner face of the f lap; (iii) Ile-50 has
hydrophobic interactions at the distance of both the d and g
carbons; (iv) the three glycine residues in theb-turn of the f lap
are virtually intolerant of substitutions. Among these mutant
PRs, we have identified changes in both kcat and Km. These
results establish the nature of the side chain requirements at
each position in the f lap and document a role for the f lap in
both substrate binding and catalysis.
The retroviral protease (PR) is encoded in the viral pro gene
for all retroviruses, including HIV-1 (reviewed in refs. 1 and
2). Proteolytic processing of the viral Gag and Gag–Pro–Pol
precursor proteins by the viral PR is a required step in the virus
life cycle. The active form of PR is a homodimer with an active
site composed of the carboxylate side chains of two aspartic
acid residues, one from each subunit of the dimer (3–7). The
presence of aspartic acid residues at the active site makes the
retroviral PRs members of the aspartic proteinase family of
enzymes (8). The aspartic proteinases are a large family of
enzymes with diverse functional roles that also share a number
of structural features (reviewed in refs. 9 and 10). One such
feature is called the flap, which lies above the active site cleft.
A short region of sequence similarity can be discerned within
the flap of distantly related retroviral PR sequences (11). By
sequence alignment, the conserved sequence domain of the
flap begins at position 47 of the HIV-1 sequence and extends
through the glycine at position 52. Sequences between these
points align in length and in a pattern: aliphatic-Xaa-Gly-
aliphatic-small-Gly. In the HIV-1 PR, these residues combine
to give a short stretch of b-sheet followed by a turn that ends
with the conserved glycine at position 52 (12).
One powerful approach to the study of function is the use of
large-scale genetic screens. Expression of a protein or an RNA,
or use of a DNA control element, either in its homologous
setting or in a convenient heterologous setting under condi-
tions where function can be monitored, can represent a useful
starting point for a detailed functional analysis using mutagen-
esis. Such approaches usually allow a breadth of analysis that
is not possible using traditional assays. The strategy of a
large-scale genetic screen is generally applicable and has been
applied to a diverse set of biological systems (for examples, see
refs. 13–22).
We have previously examined the sensitivity of the entire
HIV-1 PR to randomly incorporated mutations and observed
that the flap is one of three regions within the PR that display
consecutively placed, mutationally sensitive amino acids (23).
Using saturation mutagenesis, we have extended those studies
to determine in detail the sequence requirements of each
position of the HIV-1 flap. In this report, we describe the
activity of 131 PRmutants with single amino acid substitutions
in the HIV-1 flap region. In addition, we have examined the
catalytic properties of several of the PR flap mutants. The
properties of these mutants indicate that the flap participates
in both substrate binding and catalysis.
METHODS
Mutagenesis and Expression of the pART2 Vector Express-
ing pro and pol.Mutations within the HIV-1 PR domain were
introduced into the proypol expression vector pART2 (23, 24).
This plasmid contains a 3.7-kb fragment of the HIV-1 genome
(BglII to SalI from the HXB2 infectious clone of HIV-1; ref.
25) inserted into the bacterial expression vector pIBI20. The
oligonucleotide-directed mutagenesis procedures used have
been described previously (23, 26, 27). The mutagenic oligoase
long nucleotide in each reaction was a 27-base long oligonu-
cleotide complementary to the HIV-1 PR coding domain.
Three nucleotides which corresponded to a particular codon
within the flap coding region were randomized during oligo-
nucleotide synthesis; the three randomized positions were
always placed 14 nt downstream of the 59 end of the oligonu-
cleotide.
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The analysis of PR activity after induction of expression was
as described (23, 24). Western analysis of bacterial lysates from
bacteria expressing the Pro–Pol fusion protein was performed
using a monoclonal antibody (NEA-9304; DuPontyNEN) to
detect the extent of processing of reverse transcriptase within
the Pol domain. We have included in our present analysis 40
mutants that were previously reported (23). In addition,
mutants with changes at position 56 have been screened for
temperature sensitivity (28). Some of the mutants were eval-
uated with an alternative bacterial growth protocol to improve
the regulation of the lac promoter before induction (29), which
resulted in several minor changes in phenotypic assignment
(23).
Mutagenesis of pETPR Vector Expressing PR. To produce
HIV-1 PR for the analysis of enzyme kinetics, the HIV-1 PR
coding domain was inserted into XbaI and HindIII sites of
pET-24a(1) (Novagen). The inserted PR-encoding fragment
included an initiation codon and termination codon flanking
the 99 codons of the pro gene. Site-directed mutagenesis to
incorporate selected mutations was conducted as described
above.
Enzyme Activity Assays. Expression of the HIV-1 PR was
induced with isopropyl b-D-thiogalactoside (IPTG) in Esche-
richia coli transformed with pETPR expression vector. The PR
was purified from inclusion bodies and refolded as described
previously (30). Active site titration was done using the HIV-1
PR inhibitor SKF922 (Ki, '1 nM) with Eo and Ki determined
by fitting the Morrison equation (31). Two substrates were
used to assay enzyme activity. For the substrate KARVLy
AEAMSF(NO2) [LeuyAla substrate; F(NO2) is used to des-
ignate nitrophenylalanine, which functions as a chromophore],
the reactions were performed at 378C in 100 mM NaOAc, 1 M
NaCl, 1 mMEDTA, and 0.1% polyethylene glycol (PEG) 8000
(32), pH 6.0, for 30 min, with ,20% substrate cleavage.
Reactions were terminated by adding 500 ml of 3% trif luoro-
acetic acid (TFA), and 200 ml of the reaction mixture was
analyzed by HPLC. Substrate and product were separated
using a Waters DELTA PAK 5-micron C18 100A column on
a Waters HPLC, and integrated peak areas were calculated
using the Waters Millennium Chromatography Manager. Ki-
netic parameters were calculated using ENZFIT.
For the fluorogenic substrate KAVYyF(NO2)EANle(NH2),
the reactions were performed in 1.25 M (NH4)2SO4, 6.25 mM
DTT, 0.125 M N-(2-acetamido)-2-aminoethane-sulfonic acid
(ACES), 0.1% PEG 8000, pH 6.2 (33, 34). The reactions were
monitored with a Perkin–Elmer Luminescence Spectrometer
LS50B at 277-nm excitation wavelength and 306-nm emission
wavelength. The total reaction volume was 600 ml, and reac-
tions were monitored for 2 min.
RESULTS
Activity of HIV-1 PR Mutants Assayed with a Bacterial
Expression System. We previously showed that several posi-
tions in the flap region of the HIV-1 PR are sensitive to
nonconservative amino acid substitutions, resulting in the loss
of PR activity (23). We have extended these studies to deter-
mine the sequence requirement at each position of the flap,
starting with the methionine at position 46 (Met-46) and
extending through the valine at position 56 (Val-56). These 11
aa form an antiparallel b-sheet that extends over bound
substrateyinhibitor, with positions 49–52 forming a turn at the
end of the flap (Fig. 1). A total of 131 independent substitution
mutations were identified within this 11-codon stretch; this
represents'63% of all possible single amino acid substitutions
within this region.
The mutations were introduced into the PR coding domain
as part of theHIV-1 pro–pol expression vector pART2 (23, 24).
When expression of this plasmid was induced in E. coli, a
polypeptide containing the viral PR, reverse transcriptase
(RT), and integrase was synthesized. When the viral PR is
active, this large protein is processed to give mature Pro and
Pol protein products of the same size as those found in virus
particles (23, 24, 35, 36). The activity of the viral PR was easily
monitored by the appearance of the two processed forms of the
reverse transcriptase (p66 and p51; Fig. 2, lanes 1 and 2). In the
absence of processing, the complete translation product en-
coded in the pro and pol genes (p120) was seen along with a
series of aberrant products that do not have the expected sizes
of the viral RT (Fig. 2, lane 3). For somemutants, intermediate
processing of the Pro–Pol precursor protein was seen, with
some of the precursor remaining unprocessed (see Fig. 2, lane
6). The range of phenotypes seen with substitutions at each
position is shown in Fig. 2, and the phenotypes of all of the
mutants are listed in Table 1.
In this discussion, the positions within the flap are divided
into three groups. The first group includes those with side
chains extending outward toward solvent: Met-46, Phe-53, and
Lys-55. The second group includes those in theGly-rich region:
Gly-48, Gly-49, Gly-51, and Gly-52. The third group includes
those with a hydrophobic chain extending inward: Ile-47,
Ile-50, Ile-54, and Val-56. As shown in Table 1, those positions
with side chains extending out were most tolerant to substi-
tution, suggesting that these residues do not participate in
critical interactions. For Met-46, the most active substitutions
at this position were hydrophobic amino acids, while polar and
charged amino acids gave only intermediate activity. Similarly
for Phe-53, hydrophobic amino acids gave wild-type activity
FIG. 1. Flap region of the HIV-1 PR. (A) The a carbon tracing of
the HIV-1 PR is shown with the positions of the flaps indicated. The
active site aspartic acid residues are shown in wireframe under the
bound inhibitor (shown in space filling), and the N and C termini of
the two chains of the dimer PR are shown, with the prime (9) used to
indicate one of the two chains. This figure was generated using the
coordinates of the structure of the HIV-1 PR bound to the inhibitor
A-77003 (57). (B) The HIV-1 flap regions in thick line overlaying the
inhibitor A-77003 (57). The chain orientation is shown in parentheses.
Structures were evaluated using MACIMDAD.
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while either charged, polar, or small amino acids gave only
intermediate activity (Table 1). However, for Lys-55, charged,
polar, and hydrophobic amino acids all gave full activity (Table
1).
Those positions belonging to the Gly-rich region, with the
exception of Gly-48, are the most sensitive to substitution.
None of the amino acids tested gave activity except for Gly-51
3 Ala. For Gly-48, however, a variety of amino acid substi-
tutions, including polar and basic amino acids, gave full
activity. Hydrophobic amino acids tended to give lower activ-
ity. Acidic amino acids and proline were the least tolerated. An
aspartic acid substitution destroyed activity, while substitution
with glutamic acid altered the specificity of the PR. As noted
previously, the Gly-48 3 Glu substitution showed reduced
processing at the internal cleavage site of the reverse tran-
scriptase, giving reduced amounts of the p51 RT product (Fig.
2, lane 13; see ref. 23).
For those positions with a hydrophobic side chain extending
inward, Ile-47, Ile-50, Ile-54, and Val-56, only a few conser-
vative substitutions were tolerated. None of the 15 aa tested at
Ile-47 gave wild-type activity, although cysteine and valine
gave intermediate activity (Table 1). The isoleucine at position
50 could be substituted with leucine or valine and retain
substantial activity. For Ile-54, two conservative substitutions,
leucine and valine, gave full activity, while two nonconserva-
tive substitutions, cysteine and threonine, gave intermediate
activity. For Val–56, only two amino acid substitutions, threo-
nine and cysteine, gave wild type-like activity (Table 1). For
this group of positions, the tolerated substitutions are aliphatic
and hydrophobic, and the pattern of sensitivity is distinctive for
each position suggesting nonequivalent hydrophobic environ-
ments.
Kinetic Analysis of Selected HIV-1 PR Mutants. PR mu-
tants representing the three groups were selected for kinetic
analysis. Ile-50 3 Val and Ile-54 3 Thr are mutants of the
group with side chains extending inward, Gly-51 3 Ala
represents a mutant in the Gly-rich region, and Phe-533 Asp
represents a member of the group with side chains extending
outward toward solvent. Two substrates were used in the
analysis of enzyme kinetics. Data for the substrate LeuyAla,
which represents the processing site between CA and p2 in the
Gag polyprotein precursor, are shown in Table 2. Wild-type
PR has a Km of 0.49 mM and kcat of 8.5 s21. Ile-503 Val has
an'6-fold increase in Km and no change in kcat. Gly-513 Ala
has a ,2-fold increase in Km and an '6-fold decrease in kcat.
For Phe-533 Asp, Km and kcat are slightly lower than those of
wild type. The Km of Ile-543 Thr is too high to be measured
accurately due to limited solubility of the substrate.
As an alternative way to assess the activity of the Ile-54 3
Thr mutant on the LeuyAla substrate, the initial velocity of the
reaction catalyzed by the Ile-54 3 Thr mutant was measured
at 0.05 mM substrate concentration to derive kcatyKm from the
equation V5 (kcatyKm)3 E3 S. The Ile-543 Thr mutant has
a kcatyKm of 0.2, which is '30-fold less than the wild-type
enzyme.
Kinetic analysis of the mutant PRs was also carried out using
the fluorogenic substrate, KAVYyF(NO2)EANle-NH2, and
the results are also shown in Table 2. All of the mutants had
similar differences compared with the wild-type enzyme using
either substrate.
Activity of a PR Mutant with an Alternative Flap Sequence.
A comparison of the HIV-1 PR sequence with the sequences
of other retroviral PR flap regions (11) reveals that at multiple
positions within the flap there are substitutions in other
retroviruses that are incompatible with activity of the HIV-1
PR. To examine how the retroviral PR flap can accommodate
a different sequence and still function, we made a flap mutant
with the entire sequence of human leukemia virus type 2 flap
(GGIGG to LGASG). No PR activity was detected with this
mutant PR using the fluorogenic substrate (data not shown).
This result indicates that this different flap sequence is not
equivalent and that other changes must be present elsewhere
within either the PR or the substrate to compensate for the
alternative flap sequence present in the human leukemia virus
type 2 flap. A similar conclusion of nonequivalence of flap
sequences has been drawn from studies comparing the PRs of
Rous sarcoma virus and HIV-1 (37–39).
DISCUSSION
The flap plays a central role in the activity of the retroviral PR.
It must move away from the active site to allow the entry of
substrate and the exit of products. In the down position,
interacting with substrate, the two flaps of the dimer PR
coordinate a water molecule that helps position the substrate
for catalysis. Alteration of the backbone atoms of the HIV-1
PR flap that coordinate this water molecule profoundly affect
kcat (40). The crystal structure of the PR suggests other
important backbone and side chain interactions involving the
flap contribute to PR activity and substrate specificity (12, 41,
42). We have used large-scale mutagenesis in an effort to
define the side chain requirement at each position of the
FIG. 2. Western analysis of HIV-1 PR mutants. Extracts from bacteria expressing either the wild type or a PR mutant of pART2 were
electrophoresed in a polyacrylamide gel under denaturing conditions. The proteins in the gel were transferred to nitrocellulose and analyzed for
the presence of processed reverse transcriptase. p120 indicates the position of the unprocessed Pro–Pol protein precursor, and p66 and p51 indicate
the positions of the processed forms of HIV-1 reverse transcriptase. Lane 1 shows staining of reverse transcriptase isolated from virus particles.
Lane 2 is the extract from a bacterial culture expressing the wild-type Pro–Pol from the pART2 expression vector. Lane 3 is a negative control
for processing in which the codon of the catalytic aspartic acid was changed to encode alanine (D25A) in the pART2 expression vector. Lanes 4–29
are examples of PR mutants with changes at each of 11 positions in the flap [Met-46 (M46) through Val-56 (V56)]. The amino acid substituted
in each mutant is shown at the top of the lane using the single letter abbreviation for amino acids.
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HIV-1 flap as a way of assessing the environment and con-
tribution of each of these residues. Changes at 4 of these 11
positions within the flap have been associated with resistance
to PR inhibitors. Several of the mutants presented here have
been described previously by others (43–46), and there is good
but not complete agreement with these previous results.
The Solvent-Exposed Face. Only one of the three residues
that are oriented toward solvent on the face of the flap behaves
as a surface residue (Fig. 3). There is little change in activity
when position 55 is substituted from lysine to a variety of other
amino acids, as would be expected for a typical solvent-
accessible surface residue. In contrast,Met-46 and Phe-53 both
behave as if they are involved in important hydrophobic
interactions (Table 1), although this effect was more apparent
in the bacterial expression system compared with the activity
of the purified PR mutant Phe-53 3 Asp using two peptide
substrates (Table 2).
There are several possibilities that could explain the hydro-
phobic nature of these residues. First, Met-46 and Phe-53 form
a cleft between them that could interact with substrate. The
substrate sequence beyond the P4 amino acid (which has a
shallow pocket at the edge of the substrate binding cleft) has
been shown to affect PR cleavage (47), possibly indicating the
existence of interactions on the surface of the PR beyond the
substrate binding cleft, although such distal side chain inter-
actions have not been observed using structural analysis (41).
Another possibility is that these hydrophobic residues affect
movement of the flap and dehydration of the active site (48).
Changes at position 46 to other hydrophobic amino acids are
frequently found after selection for resistance to PR inhibitors
that themselves do not extend beyond the substrate binding
cleft (49, 50). Taken together, these results indicate that the
residues at positions 46 and 53 contribute as hydrophobic
residues to PR activity in an important but as yet poorly
understood way.
A Hydrophobic Patch on the Inside of the Flap. Ile-47,
Ile-54, and Val-56 are involved in hydrophobic interactions,
with Ile-47 sitting just above Val-32 in the hydrophobic core
(Fig. 4A). This is a highly organized structure as can be inferred
by the distinctive patterns of activity seen after substitution at
each position. Substitution with leucine had no apparent effect
on position 54 but was incompatible with activity at position 47
(Table 1; see also ref. 45). In contrast, mutants with a
FIG. 3. The outer face of the flap. a carbon tracing of the flap
region with the side chains for residues Met-46, Phe-53, and Lys-55 is
shown. In addition, the locations of the glycines at positions 48, 49, 51,
and 52 are shown. This figure was made using the structure of the PR
bound to the inhibitor A-77003 (57).
Table 1. Activity of HIV-1 PR mutants
Level of
activity
Substitutions at indicated flap positions
M46 I47 G48 G49 I50 G51 G52 F53 I54 K55 V56
Wild-type Val Ser Leu Tyr Leu Thr Thr
Trp Thr Leu Val Asn Cys
Phe His Ile Ile






wild-type His Val Phe Val Ser
Arg Val





negative Gln Thr Gly
Gly
Negative Pro AspAsp Trp Tyr Leu Asn His Leu
Ala Pro Ala Asn Thr His Asp Ile
Leu Asp Thr Arg Lys Asn Trp
Arg Ser Ala Pro Asp Arg Ser
Met Phe Trp Cys Ala Lys Ala
Asn Gln Ser Lys Phe Gly Glu
Gln Arg Gln Val Val Pro Arg
Gly Val Lys Met Ser Ala Lys
Tyr Glu MetPhe Pro Ser





The level of protease activity was assessed based on results from
Western analysis. A mutant was considered to have a wild-type level
of activity if the Pro–Pol precursor was completely processed. A
negative phenotype was assigned when no correct processing to
generate either the p66 or p51 form of RT was seen. An intermediate
phentoype was assigned when some, but not complete, processing was
observed. The intermediate phentoype was further subdivided based
on whether the activity was nearly wild-type, nearly negative, or in
between. One-letter abbrevations for amino acids are used, followed
by the position number.
Table 2. Kinetics of flap mutants
Enzyme
Substrate
KARVLyAEAMSF (NO2) KAVYyF (NO2) EANle-NH2
Km, mM kcat, s21 kcatyKm Km, mM kcat, s21 kcatyKm
Wild-type 0.49 8.5 17.3 3.7 13.4 3.6
Ile-50 3 Val 3.13 8.3 2.7 16.4 19.5 1.2
Gly-51 3 Ala 0.73 1.5 2.1 2.2 2.6 1.2
Phe-53 3 Asp 0.21 3.9 18.6 6.9 15.0 2.2
Ile-54 3 Thr .5 ND ND 20.4 1.5 0.1
ND, not determined. One-letter abbreviations for amino acids are used.
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substitution to valine at either 47 or 54 showed wild-type or
nearly wild-type activity (Table 1; see also ref. 44) but no
activity when the long aliphatic side chain was replaced with
alanine (Table 1). Val-56 could not be changed to either of the
longer aliphatic amino acids (leucine or isoleucine) but was
active when substituted with the isosteric but more polar amino
acid threonine, the wild-type amino acid found in the HIV-2
PR. This is in contrast to positions 47 and 54, which showed
good activity when substituted to valine but little or no activity
when substituted to threonine (Table 1). These results indicate
both tight and highly organized packing of these residues in the
flap. The inability of Ile-47 and Val-56 to accept leucine may
be due to the internally oriented, close interaction between the
aliphatic side chains of these two residues (Fig. 4A). By
contrast, the side chain of Ile-54 is much closer to the surface,
perhaps allowing for repacking to accommodate leucine.
Ile-50 can participate in both the S1yS19 and S2yS29 subsites,
although in an asymmetric way (Fig. 4B). The d carbon can be
involved in hydrophobic packing within the flap or extend out
toward solvent, with the g carbons making contacts with bound
inhibitors in either orientation. Thus, while a valine substitu-
tion would reduce some of the internal packing, it would not
preclude continued interaction with substrate, consistent with
the near wild-type level of activity that was observed with the
Ile-50 3 Val mutant (Table 1). However, the loss of the
internal packing of the d carbon may provide more flexibility
to the remaining atoms of the side chain. This explanation
could account for the appearance of Ile-50 3 Val as a
substitution associated with at least partial resistance to some
PR inhibitors (51), and our observation that this substitution
selectively affects Km but not kcat (Table 2). By contrast, the d
carbon of Ile-47 is in contact with the P2yP29 side chains of the
inhibitorysubstrate. Substitution to valine has been reported to
have a modest effect (2- to 3-fold) on both Km and kcat (44).
This mutation has also been reported to affect sensitivity to
some PR inhibitors (51). In the simian immunodeficiency virus
SIVmac and HIV-2 PRs, position 47 is naturally occupied by
valine, but in these cases the position 32 residue is isoleucine
rather than the valine found in the HIV-1 PR; this may
represent a compensatory mutation since in each case the d
carbon of the isoleucine (Ile-47 of HIV-1 and Ile-32 of SIVmac
and HIV-2) is in approximately the same position (52, 53).
Glycines in the Turn. Because of their positions in the turn
of the flap (Fig. 3), the glycines at positions 49, 51, and 52 are
severely constrained in their ability to accommodate a side
chain (A. Wlodawer and A. Gustchina, personal communica-
tion). Thus it is not surprising that these positions are nearly
intolerant of any substitutions (Table 1). A similar conclusion
has been drawn for the glycine at position 69 in the Rous
sarcoma virus PR (equivalent to position 52 in the HIV-1 PR)
based on its sensitivity to substitution with leucine (37). The
one exception to the intolerance of these glycines is seen in the
active HIV-1 PR with the conservative substitution alanine at
position 51. The addition of a methyl group on the top of the
flap is unlikely to allow for a new direct interaction with
substrate. This substitution selectively affects kcat (Table 2). It
is possible that the addition of the methyl group leads to
changes in f-c angles in the flap that compromise its ability to
participate in catalysis. By analogy to the work of Baca and
Kent (40), if the Gly-51 3 Ala substitution caused a reposi-
tioning of the main chain nitrogens of Ile-50, then the coor-
dinated water molecule under the flap might be either more
difficult to trap or improperly positioned, leading to a reduced
kcat, although other explanations are also possible.
The exception to the highly sensitive glycines in the flap is
Gly-48, which is adjacent to the turn within the flap. We have
previously shown that a glutamic acid substitution at this
position restricts the specificity of the PR, as seen by limited
cleavage of the processing site within p66 RT to generate the
p51 subunit (23). We also showed that this restriction was due
to an unfavorable interaction with the P39 amino acid, which
selectively affected Km (54). A side chain at position 48 could
potentially interact with either the P1yP19 or P3yP39 side
chains. Position 48 is very tolerant of substitution when assayed
using the bacterial expression assay (Table 1), and a similar
tolerance to substitution has been seen with purified recom-
binant PR (46, 54). Selection with the PR inhibitor saquinavir
results in the appearance of a Gly-48 3 Val substitution (55,
56), again indicating the potential impact of a side chain at
position 48 on ligand binding specificity.
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FIG. 4. Hydrophobic interaction in the flap region. (A) Stereoview
of the interactions between residues Ile-47, Ile-54, and Val-56 within
the flap and the underlying residue in the hydrophobic core Val-32.
This figure was made using the structure of the PR bound to the
inhibitor A-77003 (57). (B) Stereoview showing the interactions of
Ile-47 (and Ile-47 from the other subunit designated I147) and Ile-50
(and Ile-50 from the other subunit designated I150) with the bound
inhibitor U-85548e. Q201 represents the P3 amino acid glutamine of
the inhibitor. (P1 represents the substrate amino acid to the N-terminal
side of the scissle bond, P2 is next to the P1 residue continuing toward
the N terminus, with P3 being next to P2, etc. P19 represents the
substrate amino acid to the C terminus of the scissle bond, with P29
being next to P19, etc. S1 represents the pocket in the PR that
surrounds the P1 side chain, S2 surrounds the P2 side chain, etc.) This
figure was made using the coordinates of the structure of the PR bound
to U-85548e (15).
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